Drug Trials

Alzheimer's drug trial launched

BBC News (Free subscription) | yesterday

A treatment which may help prevent the onset of advanced Alzheimer's is to be tested in a ground-breaking, Glasgow run, year-long clinical trial.

Alzheimer's drug trial launched

BBC Sport (Free subscription) | yesterday

A treatment which might help prevent the onset of advanced Alzheimer's disease is to be tested in a trial in Glasgow.

Synexus Leads The Way In South Africa With Vital Paediatric Vaccines Trial

Medical News Today (Free subscription) | 4 hours ago

UK-based Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials, recruited the highest number of patients to the South African study investigating a paediatric vaccine against rotavirus. The company recruited more than 2000 children aged between 5 and 10 weeks in 3 months, making Synexus the largest single source of subjects for this Phase III...

• Synexus Leads the Way in South Africa with Vital Paediatric Vaccines Trial - Business Wire

Beardsworth(R) Selects OmniComm Systems' TrialMasterTM Solution For The Electronic Data Capture (EDC) Of A Phase II Vaccine Study

Medical News Today (Free subscription) | 15 hours ago

OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm's TrialMaster EDC solution for conducting a Phase II vaccine study. The 3-year, 10-site study is planning to enroll 340 subjects. "After a careful...

• OmniComm Systems, Inc.: Beardsworth(R) Selects OmniComm Systems' TrialMaster(TM) Solution for the Electronic Data Capture (EDC) of a Phase II Vaccine Study - Market Wire

Helping Preschoolers To Achieve Asthma Control

Medical News Today (Free subscription) | 17 hours ago

Asthma is the commonest chronic disease in children and a major reason for admissions to hospital, yet inadequate asthma control is present in 26% to 45% of children, states a review http://www.cmaj.ca/embargo/cmaj071638.pdf in CMAJ (Canadian Medical Association Journal).

Fat Around The Middle Increases The Risk Of Dementia

Medical News Today (Free subscription) | yesterday

Women who store fat on their waist in middle age are more than twice as likely to develop dementia when they get older, reveals a new study from the Sahlgrenska Academy. The study has just been published in the scientific journal Neurology. "Anyone carrying a lot of fat around the middle is at greater risk of dying prematurely due to a heart attack or stroke," says Deborah Gustafson, senior...

• Fat Around The Middle Increases Dementia Risk - Red Orbit
• Fat around the middle increases the risk of dementia - Eurekalert
• See the 5 articles on the same subject

Pharmasset: hepatitis C drug trial will continue

Rocky Mount Telegram - Business (Free subscription) | 11/23/2009

NEW YORK — Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical ...

Pharmasset: hepatitis C drug trial will continue

Miami Herald (Free subscription) | 11/23/2009

Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical trial of RG7128, a drug that is designed to treat the liver disease hepatitis C.

Pharmasset: hepatitis C drug trial will continue

San Fransisco Chronicle (Free subscription) | 11/23/2009

Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical trial of RG7128, a drug that is designed to treat the liver disease hepatitis C. An independent committee reviewed data from the first 100 subjects enrolled in the midstage... Liver - Hepatitis C - Hepatitis - Clinical trial - Health

• Pharmasset: hepatitis C drug trial will continue - Seattle Times
• Pharmasset: Hepatitis C Drug Trial Will Continue - ABC News
• See the 4 articles on the same subject

POZEN Announces Start Of Enrollment For PA32540 Phase 3 Program

Medical News Today (Free subscription) | 11/23/2009

POZEN Inc. (NASDAQ: POZN) announced the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.

ImmuPharma Announces Final Results Of PhaseIIb Study Of LUPUZOR™ In Lupus

Medical News Today (Free subscription) | 11/23/2009

ImmuPharma PLC announced the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.

Medication Plus Parent Training Improves Behavioral Problems In Children With PDD

Medical News Today (Free subscription) | 11/23/2009

Treatment that includes medication plus a structured training program for parents reduces serious behavioral problems in children with autism and related conditions, according to a study funded by the National Institute of Mental Health (NIMH). The study, which was part of the NIMH Research Units on Pediatric Psychopharmacology (RUPP) Autism Network, was published in the December 2009 issue of the...

• Autism: Parent training complements medication for treating behavioral problems in children with PDD - Science Daily
• Parent Training Complements Medication For Behavioral Problems In Children With PDD - Red Orbit

Immunology Expert At Children's Hospital Receives APS Prize For Patient-oriented Research

Medical News Today (Free subscription) | 11/23/2009

A pediatric immunologist at The Children's Hospital of Philadelphia has received a prestigious annual award from the American Philosophical Society, an organization founded in 1743 by Benjamin Franklin. Jordan S. Orange, M.D., Ph.D., received the Society's Judson Daland Prize for his contributions to research and treatment of inherited immune deficiency diseases. The Judson Daland Prize for Clinical...

Advanced Biliary-Tract Cancers: Promising New Drug Regimen

Medical News Today (Free subscription) | 11/23/2009

An article published Online First in The Lancet Oncology reports that bevacizumab given in addition to the combined chemotherapy regimen of gemcitabine and oxaliplatin (GEMOX-B) is well tolerated. In addition, it shows promising antitumor activity in patients with advanced biliary-tract cancers. The article reviews the survival and tumour response that compare favourably with earlier studies in patients...

Effect Of Real-Time CPR Feedback Reported At Resuscitation Science Symposium

Medical News Today (Free subscription) | 11/23/2009

Emergency medical service (EMS) providers in the United States assess an estimated 350,000 cardiac arrests each year. Only 5 to 10 percent of people who have sudden cardiac arrest survive. Better quality cardiopulmonary resuscitation (CPR) provided by prehospital EMS providers may be associated with better patient outcome. The Resuscitation Outcomes Consortium (ROC) is the largest clinical research...